aibioDisclosures and method
Not investment advice
Everything on aibio.space is general information and opinion, written for all readers alike. Analysis pieces carry a rating (see below), which is our opinion of how the shares may do against other biotech stocks. Nothing here is personal advice: it does not consider your finances, goals or the rest of your portfolio, and nothing on the site tells you to buy or sell a security.
Conflicts of interest
People who run or write for aibio.space may work for, advise or hold shares in biotech or pharmaceutical companies. We leave out of our coverage and our directory any company that employs someone who runs the site. If an author holds a position in a company covered in a story or ranked on a desk, the page says so.
Paid company content
Companies can buy a Company Channel (first month free, then US$169 a month) to publish their own posts and articles on their company page. Every such post is labeled as company content, names the company that wrote it, and states that the company pays aibio.space US$169 a month for the channel (or will from the end of its free month). This is the disclosure of consideration that section 17(b) of the US Securities Act of 1933 requires. Company posts are the company's own statements, not our reporting, and we do not check or endorse them. Until a company takes a channel, our editors manage its page.
Payment never buys, changes, softens or removes our stories, desk views, Investor Rank or Fact-check-o-meter, and it never affects our corrections decisions. No company pays us for coverage.
How news is written
Every story summarises reporting or a filing that is already public, in our own words, and links to it. The date is the date of the original report. We add no figures that the source does not contain.
How analysis is written
Analysis pieces are opinion, labelled as opinion, on one company at a time, written the way a stock analyst writes a research note. We draft them with AI tools from the company's own SEC filings, FDA documents and trial registries, never from other publishers' coverage. Every number is checked against its source by a separate fact-check, and an editor reviews and approves each piece before it is published. Each piece sets out our reasoning step by step, tests what management says against the numbers, works out what the share price already assumes, gives the bull case and the bear case with the weight we put on each, lists the coming events that will test the call, and names what would make us change it. Every figure links to its source. Charts use the values the company tagged in its financial statements; values we derive are labelled.
Each piece ends in a rating over the next 12 months. Outperform means we expect the shares to do better than the average US-listed biotech stock. Neutral means about the same. Underperform means worse. Conviction (high, medium or low) says how sure we are. A rating is set against the share price named on the piece, from a filing or a dated exchange close, and is only as current as that date; we review it when the company reports or the facts change, and a revised piece carries its new date. We never set price targets. Ratings can be wrong. Companies cannot pay for an analysis, review it in advance or change its rating; they can ask for a correction or a reply.
How desk views are written
A desk view is opinion, labelled as opinion. It covers five things: the technology, the odds at the FDA, the balance sheet, the main risk and what to watch next. Every figure links to its source, usually the company's own filings.
For the odds, we start from published base rates. From 2011 to 2020, 90.6% of all new drug and biologic filings in the US went on to approval, and 93.6% of those in rare diseases did (BIO, Informa and QLS). Base rates are averages, not forecasts for one drug.
Pictures
Photographs are public-domain or openly licensed images of laboratories, markets and cells. They show the world the companies work in, never a company's own labs or people. Credits are in every page footer.
How the Investor Rank works
The aibio.space Investor Rank is a number from 1 to 10 shown on each full company desk. It is our opinion of the company's business position, built from the analysis on the desk. We score five things from 0 to 2: the technology, the odds of the next approvals and readouts, the balance sheet, how manageable the main risk is, and momentum in sales and catalysts. The total, with a minimum of 1, is the rank. 1 and 2 are our most negative view, 9 and 10 our most positive. Colors go from red at 1 to green at 10, and the number and label always appear with the color.
The rank is opinion only. It is not a recommendation to buy, sell or hold any security and it is not investment advice. It does not consider the share price, valuation, your financial situation or your goals. It can be wrong and it can change at any time. Companies cannot pay for a rank, and a Company Channel has no effect on it. Companies without a full desk are not ranked.
Corrections and right of reply
We correct verifiable errors of fact promptly, on the page itself, with a dated note at the bottom saying what changed. We do not quietly edit or remove accurate reporting, and we do not take payment for coverage, for changes or for removals. A company that disputes an opinion in a desk view can ask for a reply; where the reply adds facts or a fair counterpoint, we publish it, linked from the piece. Send requests through the reputation management form or to contact@aibio.space.